Dublin 20th September 2011 – Taoiseach Enda Kenny today announced that Pfizer, the world’s leading Biopharmaceutical Company, is to make a substantial investment of $200 million (€145m) at its Grange Castle biotechnology manufacturing facility in Clondalkin, Co. Dublin.
The investment will enable Pfizer to introduce two new processing suites to the site and expand current production and product testing capabilities. This investment has resulted in the generation of significant construction employment (up to 400 jobs) during peak construction periods.
Pfizer’s Grange Castle facility is one of the largest biotech manufacturing sites in the world and currently produces two of the company’s blockbuster medicines – Enbrel and Prevenar 13. The Grange Castle facility is strategically important to Pfizer globally. Since opening in 2005, it has evolved into a highly specialised site for manufacturing, testing and developing medicines for patients around the world. The site currently employs approximately 1100 full time staff.
Making today’s announcement, Taoiseach Enda Kenny said, “This is very welcome news by the leading Biopharmaceutical Company in the world. Pfizer has made a tremendous contribution to Ireland’s Life Sciences industry since it first established here in 1969 and this investment is a further demonstration of the company’s continuous commitment to Ireland.”
Dr. Paul Duffy, Vice President External Supply, Pfizer Global Supply said, “Pfizer has a long record of successfully manufacturing some of our top medicines in Ireland. This investment will allow us help meet the needs of patients throughout the world by introducing new technologies and capabilities at Grange Castle, where we produce highly complex vaccines and biologic products for patients around the world.”
Frank D’Amelio, Executive Vice President and CFO of Pfizer Inc., added, “With pharmaceutical and chemical products accounting for over 50% of Irish exports and a long history in pharmaceutical excellence, Ireland is a prime location for this major investment. The Grange Castle project is a strategic initiative that will allow us to further align and strengthen our manufacturing and supply network in an environment that is continually focused on quality, flexibility and application.”
Welcoming the investment, IDA Ireland CEO Barry O’Leary said “This is a very welcome development by Pfizer in Ireland. This investment gives a substantial boost to Ireland’s Life Sciences sector and is a vote of confidence in Ireland’s attractiveness as a location for bio- pharmaceutical manufacturing. This strategic development by Pfizer coupled with the availability of world class research and training facilities in the National Institute for Bioprocessing and Training (NIBRT) and the availability of highly skilled staff positions Ireland as a leading global location for development and manufacturing of biopharmaceuticals.”
“IDA offers its continued support to Pfizer and I would like to congratulate the Grange Castle team for winning this investment to further develop this strategically important site for Pfizer worldwide”, concluded Barry O’Leary.
About Pfizer in Ireland
Pfizer is one of Ireland’s leading employers and the largest pharmaceutical investor. One of the first pharmaceutical companies to locate in Ireland (1969), Pfizer has a rich heritage of innovation and expression over a forty year period. The business has approx 4,300 colleagues across eight locations based in Cork, Dublin, Kildare and Limerick.
Pfizer’s business interests in Ireland are diverse. There is a manufacturing presence in Active Pharmaceutical Ingredients, Solid Dose Pharmaceuticals, Nutritionals, Vaccines and Biopharmaceuticals; Global Financial Services centre and a global Treasury operation.
The Irish operations manufacture some of Pfizer’s best selling and newest medicines including Lipitor (cardiovascular), Viagra (urology), Sutent (oncology), Enbrel (rheumatology) and Prevenar (vaccines). Ireland is a leading manufacturing base for Pfizer globally; exporting to global markets, Total investment by the company in Ireland exceeds $7 billion.
For further details please contact –
Press office – 01 603 4226
Published: 22nd September 2011.